BRIEF-Trius Therapeutics up in premarket after tedizolid study results

NEW YORK, March 25 Mon Mar 25, 2013 8:10am EDT

NEW YORK, March 25 (Reuters) - Trius Therapeutics Inc : * Up 6.6 percent to $7.45 in premarket after tedizolid study results

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.